Galectin-3 Peptide Biomarker Detection via Mass Spectrometry

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting cancer, particularly thyroid cancer, are not sensitive enough, leading to unnecessary surgical interventions due to inconclusive results from fine needle aspirates and enzyme-linked immunosorbent assays (ELISA), which struggle with detecting multiple protein biomarkers in biological samples.

Innovation Solution

Quantifying biomarkers derived from Galectin-3 in biological samples using mass spectrometry, specifically peptide fragments produced by digesting Galectin-3 with trypsin, allows for sensitive detection of cancer through increased biomarker levels compared to controls, enabling non-invasive testing and avoiding unnecessary surgeries.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If ELISA is used to detect Galectin-3 in biologic samples, then detection can be performed, but the sensitivity is insufficient and multiple biomarkers cannot be detected simultaneously

Engineering Contradiction:

Improvedetection sensitivityVSAvoidability to detect multiple biomarkers

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent segments the Galectin-3 protein into multiple distinct peptide biomarkers through enzymatic digestion. Instead of detecting the whole protein with a single antibody-based method, the invention identifies and detects multiple specific peptide fragments (e.g., peptides with sequences containing galectin-3 epitopes) that can be simultaneously measured, thereby achieving both high sensitivity and multi-biomarker detection capability

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent replaces the mechanical/chemical binding mechanism of ELISA (antibody-antigen binding with enzyme-linked detection) with mass spectrometry-based detection. This substitution enables simultaneous detection of multiple peptide biomarkers based on their unique mass-to-charge ratios, providing superior sensitivity and the ability to detect multiple biomarkers in a single assay without the limitations of antibody specificity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If fine needle aspirate with histological analysis is performed, then cancer detection is achieved for most cases, but non-diagnostic or follicular neoplasm results lead to unnecessary surgical removal

Engineering Contradiction:

Improvecancer detection accuracyVSAvoidunnecessary surgical intervention

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent performs preliminary detection of multiple Galectin-3 derived peptide biomarkers in fine needle aspirate samples before surgical intervention. By measuring the levels of multiple peptide biomarkers (e.g., through mass spectrometry) and comparing them to established thresholds or control samples, the method provides a more definitive pre-surgical diagnosis that can distinguish malignant from benign nodules, thereby preventing unnecessary hemithyroidectomy in benign cases while ensuring appropriate surgery for malignant cases

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the diagnostic parameters from traditional histological assessment (which may be non-diagnostic or indeterminate) to quantitative measurement of multiple peptide biomarker levels. By monitoring the concentrations of specific Galectin-3 derived peptides and their patterns, the method provides more precise diagnostic information that reduces diagnostic uncertainty and guides surgical decision-making more accurately

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides significantly improved sensitivity for detecting cancer, allowing for the differentiation between benign and malignant growths, reducing the need for hemithyroidectomy in cases of benign thyroid nodules and enabling the detection of multiple biomarkers not possible with ELISA.

Implementation Method 1

The methods generally involve quantifying the amount of one or more biomarkers derived from Galectin-3 in a biological sample from the subject by mass spectrometry

Methodology Applied

Scientific EffectMass spectrometry:

Implementation Method 2

specifically peptide fragments produced by digesting Galectin-3 with trypsin

Methodology Applied

Scientific EffectEnzymatic digestion: Enzyme

Data Source

PatentUS8945511B2Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3

Publication Date: 2015.02.03 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

AI summary

Described herein are sensitive methods for determining if a subject has cancer. The methods generally involve quantifying the amount of one or more biomarkers derived from Galectin-3 in a biological sample from the subject by mass spectrometry, wherein an increase in the amount of one or more biomarkers in the biological sample as compared to a control is an indication of the presence of cancer in the subject.